Singular Genomics Systems (OMIC) Q3 2024 earnings summary

Executive summary

• Singular Genomics develops next-generation sequencing and multiomics technologies, with the G4 platform available and G4X Spatial Sequencer in development, targeting NGS and spatial biology markets.

• Shipped first G4X Early Access instrument and two G4 systems in Q3 2024, expanding spatial sequencing capabilities.

• Presented new data at SITC conference, highlighting G4X's performance in various tissue types and single-cell immune profiling.

• The company is focusing on completing G4X development, commercializing spatial biology services, and supporting G4 customers, while continuing to invest in R&D and commercial infrastructure.

• A special committee is evaluating strategic alternatives, including a potential acquisition by Deerfield at $24.00 per share, with exclusivity granted for due diligence as of October 31, 2024.

Financial highlights

• Q3 2024 revenue was $0.4M, down 12% year-over-year, mainly from consumables; nine-month revenue was $1.6M, down 13% from the prior year.

• Net loss for Q3 2024 was $16.8M ($6.72 per share), improved from $22.4M ($9.25 per share) in Q3 2023; nine-month net loss was $63.1M.

• Gross margin remained negative at $(0.3)M for Q3 and $(0.9)M for the nine months, impacted by low sales volume, rental placements, and high support costs.

• Operating expenses decreased to $17.8M in Q3 2024 (down 27% YoY), including $2.2M in stock-based compensation and a $1.6M non-cash gain from lease modification.

• Cash, cash equivalents, and short-term investments totaled $113.8M as of September 30, 2024.

Outlook and guidance

• Operating expenses are expected to be slightly down in the near term but to increase longer term as investments in G4X, spatial biology, and commercial infrastructure continue.

• The company expects continued significant losses and negative cash flows from operations for the foreseeable future.

• Management believes current liquidity is sufficient to fund operations for at least 12 months from the report date.

• Ongoing discussions regarding a potential strategic transaction; no earnings call held for Q3 2024.